InSingulo is an innovative Swedish life science company developing proprietary single molecule microscopy technology for applications in drug discovery. We have developed a biophysical characterization platform which enables screening of drug candidates on membrane protein targets in their natural configuration, and a quantitative efficacy platform which allows us to determine the downstream response via the G-alpha pathway of ligands targeting GPCRs. All at single molecule level!

Founded in 2017 following a research collaboration between Chalmers University of Technology and AstraZeneca, InSingulo today continues with development of its proprietary technology with a highly skilled team with expertise in structural biology, biochemistry, molecular and cell biology, hardware and software engineering, and advanced image and data analysis/modelling.